Biological
TRIMER 4571 clinical trials
Also written Trimer 4571.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
5 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 5
National Institute of Allergy and Infectious Diseases (NIAID) (5)
Often tested with
Tested in the same studies.
BG505 (1) · MEDI9197 (1) · Aluminum Hydroxide (1) · TRIMER 6931 (1)
Studies
Open first, then newest update. How each study uses TRIMER 4571 is read from its arms, and is right about nine times in ten.
Testing it · 5
- A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy AdultsTerminatedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT05470400Written as Trimer 4571 (200 mcg)
- Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIVCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT05781542Written as Trimer 4571
- Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT04177355Written as Trimer 4571
- Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.Active, not recruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT06332339Written as Trimer 4571
- Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03783130Written as VRC-HIVRGP096-00-VP